Clinical Trial: A Phase 1, Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HTX-001

U.S., Oct. 10 -- ClinicalTrials.gov registry received information related to the study (NCT07867288) titled 'A Phase 1, Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HTX-001' on Oct. 05.

Brief Summary: The purpose of this study is to evaluate safety, tolerability, pharmacokinetics and pharmacodynamics of multiple doses of HTX-001 in human adult participants.

Study Start Date: Oct., 2026

Study Type: INTERVENTIONAL

Condition: Nonobstructive Hypertrophic Cardiomyopathy

Intervention: DRUG: HTX-001

HTX-001 is an investigational antisense oligonucleotide (ASO)

Recruitment Status: RECRUITING

Sponsor: Haya Therapeutics, Inc.

Disclaimer: Curated by HT Syndication....